Seventure Partners Research
Investment Thesis
Seventure Partners is a Paris-based European venture capital firm founded in 1997, and one of the leading venture capital firms in Europe. With approximately $812M under management (as of March 2026, per Natixis Investment Managers), Seventure operates as a subsidiary of Natixis Investment Managers, itself part of Groupe BPCE — one of France's largest banking groups. This institutional backing gives Seventure unique access to financial networks, sector expertise, and industrial co-investors across France and Europe.
The firm's core investment thesis is to identify and back innovative companies in two primary verticals — Life Sciences and Digital Technologies — serving as an active lead investor and long-term board-level partner to help create the European leaders of tomorrow. Seventure explicitly positions itself as "the missing link" between angel investors and traditional banks, stepping in at a strategic and often risky period of company development when few institutional investors are willing to commit.
Seventure also manages several thematic funds: Health For Life Capital™ (€160M and >€200M funds dedicated to the microbiome revolution, backed by strategic LPs including Danone and Novartis), Sport & Performance Capital™ (€80M, sport and wellness), Blue Forward Fund™ (blue economy/sustainable ocean economy), Quadrivium Seed Fund (€56M, French academic spin-offs), and AVF Fund (€24M, animal health, feed and nutrition).
Sector Focus
Life Sciences (approximately 60% of activity) spans five sub-verticals:
- Microbiome / Nutrition / Foodtech / Lifestyle — Seventure is widely recognized as a global pioneer and category leader in microbiome investing. Portfolio spans Enterome (clinical-stage OncoMimics platform), MaaT Pharma (listed on Euronext, microbiome ecosystem therapies), DayTwo (precision nutrition microbiome), Vedanta Biosciences (microbiome oral therapies), Microbiotica (living biotherapeutics), Eligo Bioscience (microbiome-targeted phage), and many others.
- MedTech / Connected Health / Digital Health — including Corwave (cardiac assist), Mauna Kea Technologies (listed, CellVizio endoscopy), Feetme (pressure sensors), CardioSecur, FIRE1, Impeto Medical, Dopavision, and others.
- Biotech & Pharmaceuticals — including Nanobiotix (listed, nanoparticle cancer therapy), Citryll (inflammation biotech), Tubulis (ADC cancer therapy), Galecto Biotech, Domain Therapeutics/Kainova, Siolta Therapeutics, MedinCell (listed), and others.
- Industrial Biotech & Cleantech — including Kebony, RevivBio, and Blue Economy portfolio companies.
- Animal Health / Animal Feed & Nutrition — managed under the dedicated AVF Fund; portfolio includes Animab, Cattle Eye, Ecto, Inspecto, Novobind, Proteon Pharmaceuticals, String Bio, Tibot, and Virovet.
Digital Technologies (approximately 40% of activity) spans:
- Fintech (including Insurtech & Regtech) — SumUp (major European payments unicorn), TransferGo (cross-border payments), Hepster (embedded insurance), Algoan (credit decisioning), Ideel (contract management), Karmen (revenue-based financing), Flexvelop (embedded financing).
- Cybersecurity — Wallix (listed PAM leader), Sekoia.io (European SIEM), YesWeHack (bug bounty), Hackuity (vulnerability management), Own Security, Wultra (post-quantum authentication).
- Retailtech / Marketplaces — Launchmetrics, Glopal, Jolimoi, Reelevant, Otoqi, Mediads (social adtech).
- Other Digital — Jobteaser (HR tech, student recruiting), Testbirds (crowdtesting), Homerez (home services), Pitchy (video creation SaaS), Siit (IT service desk), Lecturio (e-learning), Opencell (billing SaaS), Expensya/Medius (expense management).
Stage Focus
Seventure invests at all stages from seed to pre-IPO and IPO. The Quadrivium Seed Fund specifically targets very early stage French academic spin-offs. The main Life Sciences and Digital Technologies funds cover early venture through growth capital and pre-IPO. Check sizes range from €500K to €10M per round, with total exposure per company up to €20M across follow-on rounds.
Check Size
Investment amounts range from €500K ($550K) to €10M ($11M) per round, with total cumulative exposure up to €20M (~$22M) per company. The firm's breadth of fund vehicles means it can participate at sub-€1M seed rounds (Quadrivium) up to multi-round late-stage growth investments.
Lead Tendency
Seventure Partners is generally the lead investor, particularly in earlier rounds. They describe themselves as "in general the lead financial investor" and take board seats or supervisory board positions at virtually all portfolio companies. Board representation is described as "quasi systématique" (near-universal). The firm maintains active governance relationships for extended periods — sometimes exceeding 10 years.
Recent Activity
Seventure remains actively deploying from its current fund vintages. Recent investments in 2025–2026 include:
- Wultra (June 2026): Led €6.8M Series A for Czech post-quantum authentication and digital identity platform, expanding into global banking markets.
- VorteX-io (May 2026): Invested in €8.5M Series A for hydrological data and real-time water monitoring solutions (Blue Economy / climate tech).
- Mediads (May 2026): Backed €3M raise for French social adtech platform expanding to US market.
- Standing Ovation (March 2026): Participated in $34.2M Series B for precision fermentation dairy protein platform.
Portfolio Highlights
Seventure has backed more than 300 companies, achieving 150+ exits and 30 IPOs. Notable exits include:
- Santaris Pharma — sold to Roche for $450M (August 2014); RNA therapeutics pioneer.
- ArgenX — Euronext / Nasdaq IPO; became a multi-billion dollar immunology biotech.
- SumUp — Major European fintech unicorn; mobile payments company operating in 35+ countries.
- Parrot — Euronext IPO; consumer and professional drone pioneer.
- Sentryo — Acquired by Cisco Systems (2019); ICS/OT cybersecurity.
- OPi / Jazz Pharmaceuticals — Sold to Eusa for €110M.
- Cambrooke — Sold to Ajinomoto.
- IDnow — European digital identity leader, acquired.
- Vistaprint — Nasdaq IPO.
- Metabolic Explorer — Euronext IPO.
- Talentsoft — HR software, acquired.
Team
- Isabelle de Cremoux, CEO & Managing Partner — Leads the firm overall and the Life Sciences division. Former executive at Arthur Andersen, Pfizer (France and Europe), and Fournier/Abbott. Founder of Health For Life Capital. Global microbiome expert who lectures internationally. Member of France's "Conseil de l'innovation" since 2018. Degree from Ecole Centrale Paris. 25+ years international pharma and finance experience.
- Emmanuel Fiessinger, Senior Partner, Life Sciences — Senior member of the life sciences investment team.
- Pierre Aumeunier, Chief Financial Officer — Oversees financial operations of the firm.
- David Manjarres, Senior Partner, Head of Digital Technologies — Joined via the 2012 acquisition of Masseran Gestion. Former CDC-Entreprises (fund-of-funds), Tikehau Capital Advisors, co-founder of Masseran Gestion, and seven years at the French Ministry of Defence in electronics R&D and digital intelligence. ENSTA Bretagne graduate, Master's in Management of Technology from Paris IX Dauphine.
- Bruno Rivet, Senior Partner, Digital Technologies & Sport — Oversees digital and sport investments.
- Thibault Canton, Partner — Digital Technologies; co-manages the Quadrivium Seed Fund.
- Julien Cazor, Venture Partner — Based in Berlin, Germany; focuses on digital technologies in Germany and broader Europe.
- Ludovic Denis, Venture Partner — Based in Paris; fintech expert.
- Guillaume Echaudemaison, Principal, Digital Technologies.
Decision Process
Seventure employs a collegial investment committee process described as "extremely rigorous but collegial." The team conducts in-depth due diligence emphasizing the quality of the management team and the potential for a long-term trust relationship. Given the partnership structure and institutional ownership, decisions involve multiple senior partners. They are long-term shareholders, sometimes remaining invested for over 10 years.
Founder Preferences
Seventure backs innovative companies with:
- Significant addressable market potential
- Proprietary technology or know-how providing a durable competitive advantage
- Strong management teams capable of building European or global leadership positions
- Founders who value an active, long-term partnership and board-level engagement
They explicitly value team quality and the ability to establish a trust-based relationship as primary selection criteria, as much as or more than product and market potential.
Geographic Focus
France is the primary geography for most fund vehicles (especially Quadrivium, Digital Opportunities Fund, and Sport & Performance Capital). The broader European focus includes Germany (Julien Cazor based in Berlin), Switzerland, UK, and Scandinavia. For Life Sciences — particularly microbiome and biotech — Seventure also invests in North America, Israel, and Asia. AUM is approximately $812M as of March 2026 (per Natixis).